A vaccine platform has been created by attaching the target-associated antigen (TAA) for the vaccine to the extracellular domain (ecd) of the potent immunostimulatory signal CD40 ligand (CD40L). Attachment of the TAA to the CD40L promotes uptake of the TAA into dendritic cells (DCs), binding to Class I as well as Class II MHC leading to presentation of the TAA on the DCs, expansion of the TAA-specific B cell and CD8 effector T-cell lymphocytes, and induction of a memory response. In addition, the TAA/ecdCD40L vaccine can overcome anergy, induce regressions of pre-existing subcutaneous (SC) nodules of cancer cells, and induce high titers of neutralizing antibodies against viral antigens. This vaccine, which can be administered SC as a TAA/ecdCD40L fusion protein, or as expression vectors (viral or plasmid) or as a vector prime-protein boost strategy, is applicable to the development of vaccine for a wide range of cancers and infectious agents.
INTRODUCTION
The response to vaccination is often limited by the existence of anergy to particular antigens in cancer and infectious diseases, low levels of expression of Class I and Class II MHC and cytoadhesion molecules on tumor cells or other antigen presenting cells, which mediate secondary signals of T-cell activation, weak immunogenicity of target antigens, low titers of neutralizing antibodies against foreign antigens on infectious agents, and acquisition of qualitative and quantitative defects of the immune response in chronic disease, cancer and advanced chronological age.
The paper reviews the development of a vaccine strategy for cancer and infectious diseases, which is based on the attachment of the target-associated antigen (TAA) to the amino-terminal end of the extracellular domain (ecd) of the potent immunostimulatory signal CD40 ligand (CD40L). [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] Attachment of the TAA to the ecdCD40L: promotes the activation and maturation of dendritic cells (DCs), 1, 3, 5 promotes Class I as well as Class II presentation of TAA on DCs, 1 and promotes expansion of the TAAspecific T cells and B cells as a response to vaccination, even in individuals in whom there is a decrease of lymphoid cell mass 9 or anergy to the TAA. 1, 3, 5, 9 Decreased responsiveness to vaccination has been observed among immunodeficient individuals including those of advanced chronological age. [11] [12] [13] This has been attributed in part to diminished level of expression of the immunostimulatory signal CD40L, which is normally provided by CD4 helper T cells. 15, 16 In the absence of this signal, the expansion of TAA-specific T cells and B cells as a response to vaccination, is severely reduced. [11] [12] [13] [14] [15] [16] This paper will review of the role of CD40L in the immune response and then describe the TAA/ecdCD40L vaccine platform. Finally, a summary will be provided of published data describing the effect of the vaccine on the induction of cellular and humoral responses to antigens, which are on cancer cells [1] [2] [3] [4] [5] [6] [7] 9, 10 or foreign antigens on infectious agents. 8 
THE ROLE OF CD40L IN NORMAL CELLS
CD40L is expressed on CD4 helper T-cell lymphocytes during the activation of these cells, which occurs following exposure to foreign antigens on infectious agents, or to vaccination strategies. 17, 18 The CD40L on CD4 helper T cells binds to CD40 receptors on B cells, T cells and DCs. Binding of the CD40L to the CD40 receptor on DCs is followed by activation of these cells, uptake of the CD40L receptor complex, increase in the expression of surface cytoadesion molecules involved in antigen recognition, activation and expansion of antigen-specific T cells, maturation of the DCs, induction of expression of CCR7, which is associated with migration of the DC to the regional lymph nodes, and expansion of the numbers of antigen-specific B and T cells.
The kinetics of expression of CD40L and the peak level of expression are both diminished in human and mouse subjects of advanced chronological age. [11] [12] [13] [14] [15] [16] Owing to diminished expression of CD40L on CD4 helper T-cell lymphocytes during activation, there is a reduction in the extent to which antigen-specific T and B cells will be expanded in response to viral infection or because of vaccination. Opposing the effect of CD40L on the surface of the CD4 helper T cells on the DCs is the effect of the negative regulatory CD4 CD25 FoxP3 T cells, which limits the extent to which CD4 helper T cells can promote activation and TAA presentation on DCs, and activation and expansion of antigen-specific T cells and B cells.
In addition to the suppressive effect of negative regulatory T cells on DCs, there are many other mechanisms, which limit the response of the DC and antigen-specific T cells to infection, cancer or vaccination. These can include acquired functional defects in the DCs, T and B cells, which reduce the response to self antigens on cancer cells as well as foreign antigens on infectious agents.
DESCRIPTION OF THE TAA/ECDCD40L VACCINE PLATFORM
In the TAA/ecdCD40L vaccine strategy, the TAA is attached to the amino-terminal end of the ecdCD40L. As the functional binding of the CD40L to the CD40 receptor is dependent on maintenance of a homo-trimeric structure, it is important to avoid using a TAA, which is so large that it will lead to destabilization of the functional homo-trimer of the CD40L. Introduction of a linker between the TAA and the CD40L can also help reduce the perturbation of the trimeric structure of the CD40L that otherwise would occur following attachment of the TAA to the ecdCD40L. As all of the sequences that stabilize the trimeric structure of full length CD40L reside in the ecd, 19 it is possible to create chimeric proteins between the TAA and the ecd of the CD40L, which are stable homo-trimers. To avoid destabilization of the ecdCD40L through attachment of the TAA, fragments of the TAA instead of the entire TAA are usually chosen for attachment to the ecdCD40L, especially when the TAA has a large molecular weight.
Other factors to consider when choosing a fragment for attachment to the CD40L besides size, include the state of glycosylation, the presence of epitopes, which will bind to Class I as well as Class II MHC, and the function of the domain from which the TAA fragment is taken, such that antibodies induced against this region would lead to neutralization of infectious capability in a virus or other infectious agent.
The injection of the TAA/ecdCD40L protein (intradermal, subcutaneous (SC), intramuscular) leads to binding of the TAA/ ecdCD40L fusion protein to the CD40L receptor on DCs. Binding is followed by internalization into the DC, and processing in the cytoplasm of the DC, which leads to fragmentation by proteolysis of the TAA/ecdCD40L and eventually presentation of TAA fragments on Class I as well as Class II MHC. After binding of the TAA/ecdCD40L to the CD40 receptor on the DC, the following are observed: increased expression of CCR7, CD80, CD 86, Class I MHC, Class II MHC and migration of the DC to the regional lymph nodes. 1, 3 The activated mature DC, which is carrying fragments of the TAA on its Class I and Class II MHC, then interacts with antigenspecific T cells and B cells, respectively, to induce activation and expansion of those T and B cells, which carry antigen recognition receptors that bind to the TAA. 1, 3 Following this is the appearance of TAA-specific CD8 effector T cells antibodies in the intravascular space and the tumor tissue or sites of tissue infection and/or inflammation. 5 The vaccine can be administered as the TAA/ecdCD40L protein or expression vectors (viral or plasmid DNA), which encode the TAA/ecdCD40L fusion protein in a secretory transcription unit. In the following pages, the effect of administration of adenoviral vectors such as Ad-sig-TAA/ecdCD40L (V), or a combination of viral vector injections with TAA/ecdCD40 protein boosts (VPP) on the induction of a TAA-specific immune response will be described.
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RESULTS OF SC ADMINISTRATION OF TWO SC INJECTIONS OF THE AD-SIG-TAA/ECDCD40L VECTOR VACCINE (V V)
The TAA/ecdCD40L transcription unit in expression vectors for the administration of the vaccine usually includes a secretory sequence (sig) at the 5 0 end of the DNA transcription unit, followed by the TAA fragment, a linker and the ecdCD40L. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] It is important to be sure that sequences in the TAA and the CD40L, which could stabilize the TAA/ecdCD40L protein in the plasma membrane are removed. The removal of these transmembrane sequences from the TAA and the CD40L, as well as the use of a secretory sequence at the beginning of the TAA/ecdCD40L transcription unit ensures that the TAA/ecdCD40L fusion protein can be secreted and released by cells, which are infected or transduced by the expression vector encoding the TAA/ecdCD40L fusion protein. 3 In the case of the use of adenoviral vectors (Adsig-TAA/ecdCD40L), the fusion protein is released for a period of 10-14 days from the cells surrounding the injection site, which are infected by the adenoviral vector. 1, 3 Vaccination can be successfully carried out even in individuals in whom there are substantial levels of neutralizing antibodies to the adenoviral vector, because of the stoichiometric excess of the adenoviral infectious particles around the injection site, which exceed the levels of neutralizing antibodies which exist in tissues. This stoichiometric excess is usually achieved when at least 1 Â 10 10 infectious particles are injected SC, probably because of the poor penetration of the neutralizing antibodies into tissue sites into which the vectors are injected.
INJECTION OF V V CAN OVERCOME ANERGY
Two mouse model systems have been used to demonstrate that two injections of Ad-sig-TAA/ecdCD40L SC (separated by 7 days) can overcome states of anergy to the TAA: (1) mice that are transgenic in the human mucin-1 gene (hMUC1.Tg mice), and (2) mice that are transgenic in the rat Her-2-Neu protein (rHER2.Tg mice) as reported previously. 3, 5 In each case, SC injection of the Ad-sig-hMUC-1/ecdCD40L or the Ad-sig-rHER2/ecdCD40L vectors into the hMUC1.Tg or rHER2.Tg mice, respectively, results in increases of the levels of hMUC-1 or rHER2-specific CD8 effector T cells and antibodies that are sufficient to prevent engraftment and growth of cancer cell lines, which are positive for either the hMUC-1 or rHER2 antigens. In both cases, two SC injections of the vector (VV) induce an immune response, which is higher by ELISPOT or ELISA assay for antigen-specific CD8 effector T cells or antibodies than is observed following a single injection of the Ad-sig-TAA/ ecdCD40L vector. 1, 3, 5 The induction of a cellular immune response, which can suppress the growth of hMUC-1 established tumor cell lines in hMUC1.Tg anergic mice, following two injections of the Ad-sig-hMUC-1/ecdCD40L vector is much greater than that observed following administration of the Ad-sig-hMUC-1 vector, which does not contain the CD40L. 1 hMUC1.Tg mice injected with two SC administrations of the Ad-sig-hMUC-1/ecdCD40L vectors at 7 day intervals survive up to 120 days after administration of 500 000 hMUC-1-positive tumor cells, whereas unvaccinated mice are all dead by 25 days after the tumor injection. 
INJECTION OF V V INDUCES A MEMORY RESPONSE FOR GREATER THAN 1 YEAR
Immunocompetent donor mice were injected SC with 500 000 hMUC-1-positive tumor cells followed by two SC injections of the Ad-sig-hMUC-1/ecdCD40L vector (VV) at 7 days apart in MUC1.Tg mice resulted in 100% of the test mice being tumor free. 1 These data showed that the V V vaccine can induce regressions of populations of tumor cells, which are established before the vaccination. Such mice remain tumor free when challenged with 1 Â 10 7 tumor cells for at least a year. To test if this resistance to tumor growth can be transferred from the donor mice to immunoincompetent nude mice, 500 000 spleen cells were collected from the vaccinated tumor resistant donor mice 1 year after vaccination and injected intraperitoneally into nude mice, which had been injected 5 days earlier with 500 000 hMUC-1-positive tumor cells. 1 The growing tumor nodules in these nude mice were shown to regress, whereas in nude mice, which were give 500 000 spleen cells from unvaccinated mice, which had been injected 5 days earlier with hMUC-1-positive tumor cells, the tumor nodules continued to grow. This experiment showed that the V V-induced immune response was a memory response, which lasted up to 1 year. 1 TAA/ecdCD40L vaccine A Deisseroth et al
THE INDUCTION OF AN IMMUNE RESPONSE BY V V IS DEPENDENT ON THE PRESENCE OF CD8 EFFECTOR T-CELL LYMPHOCYTES, BUT DOES NOT REQUIRE THE PRESENCE OF CD4 HELPER T CELLS
As the Ad-sig-TAA/ecdCD40L infected cells release the TAA/ ecdCD40L fusion protein, it is possible that the vaccination with V V will not be dependent on the presence of CD4 helper T cells. To test this hypothesis, antibodies that were lytic to either CD4 helper T cells or to CD8 effector T cells were administered before and during the vaccination and post vaccination tumor challenge. 1 The results of these experiments were that survival of the mice after vaccination and tumor challenge was 80% at 50 days after tumor cell injection in the case of mice, which were over 90% depleted of CD4 helper T cells, whereas none of the mice given the VV vaccination and tumor challenge along with antibodies lytic for CD8 effector T cells were alive at 50 days. 1 These results suggest that the TAA/ecdCD40L vaccine can replace the permissive and immunostimulatory function of CD4 helper T cells in the immune response to vaccination.
The conclusions for the experiments with V V vaccine are that V V vaccination can overcome anergy in TAA.Tg anergic transgenic mice, that V V induces a memory response greater than 1 year, that V V immune response is TAA specific and greater than that achievable with adenoviral vector, which carry the TAA transcription unit alone without a ecdCD40L attached to the TAA, and the vaccination is independent of CD4 helper T cells.
AD-SIG-TAA/ECDCD40L VECTOR PRIME-TAA/ECDCD40L PROTEIN BOOST VACCINE INDUCES HUMORAL AND CELLULAR IMMUNE RESPONSE IN 18-MONTH-OLD MICE AS WELL AS 2-MONTH-OLD MICE
In order to test whether the immune response induced by administration of the Ad-sig-TAA/ecdCD40L V V can be increased by administration of the TAA/ecdCD40L protein, test mice that were 2 months old were given a single SC injection of the Ad-sig-TAA/ecdCD40L vector followed by one, two or three SC injections of the TAA/ecdCD40L protein, produce in bacterial cells by transfection of these cells with a plasmid expression vector containing a TAA/ecdCD40L transcription unit. 5 As stated in the introduction, immunodeficient individuals (mouse and human) including those of advanced chronological age, display an acquired defect in the rate and magnitude of expression of CD40L on CD4 helper T cells during activation or following exposure to viruses. 15, 16 This defect may explain the fact that only 20% of individuals above the age of 55 years receiving the particle inactivated multivalent yearly influenza vaccine develops fully protective neutralizing antibodies, whereas 80% of the individuals below the age of 55 years develop a completely protective neutralizing antibody response.
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The levels of antigen-specific CD8 effector T cells and antigenspecific antibodies induced by the vector alone was increased in an incremental fashion by the administration at 7 day intervals starting 7 days after the single vector injection of one, two and three SC injections of the TAA/ecdCD40L protein. Next, 2-monthold or 18-month-old test mice were injected with 500 000 TAApositive tumor cells. The tumor nodues in these test mice then were allowed to grow 5-7 days, and then the test mice were injected with a single Ad-sig-TAA/ecdCD40L vector vaccine followed by three SC injections of the TAA/ecdCD40L protein, all delivered SC at 7 day intervals. The tumor nodules were then excised. The CD8 effector T cells in the tumor nodule were then separated from the tumor cells. It was then possible to show that the level of the total number of cells in the tumor nodule, which were CD8 effector T cells, increased from 0.1% in unvaccinated mice to 1.4% in 18-month-old mice. 5 Tetramers specific for the TAA-specific CD8 effector T cells were then used to show that the percentage of the total CD8 effector T cells, which were TAA specific increased from 0.5% in unvaccinated mice to 10% in vaccinated 18-month-old mice. 5 Finally, we showed in these same 18-month-old test mice that the VPPP vaccine induced a decrement of 50% in the level of the CD4 þ CD25 þ FoxP3 þ negative regulatory T cells in the tumor tissue. 5 We then injected 18-and 2-month-old mice with the Adsig-TAA/ecdCD40L vector at day -7 and TAA/ecdCD40L protein boosts at Days 0, þ 7 and þ 14 (after SC challenge with 500 000 TAA-positive tumor cells). The growth of the tumor cells was completely suppressed in 100% of the 2-month-old mice. 5 In the 18-month-old mice, the tumor grew initially and then started to regress. Fifty percent of the 18-month-old mice became completely tumor free following administration of the 2nd and 3rd TAA/ecdCD40L protein boost. 5 This shows that even in 18-month-old mice that the administration of the TAA/ecdCD40L protein boosts can result in complete eradication of growing tumor nodules in progressor mice 50% of the time. 5 RESULTS OF ADMINISTRATION OF THE AD-SIG-HMUC-1 ECDCD40L VECTOR PRIME-HMUC-1/ECDCD40L PROTEIN BOOST VACCINE Mucin-1 was chosen as a tumor antigen to be used and tested in detail in the Ad-sig-TAA/ecdCD40L vector prime-TAA/ecdCD40L protein boost vaccine. In normal cells, this MUC-1 protein is heavily glycosylated, but in tumor or neoplastic epithelial cells this protein is hypoglycosylated revealing stretches of epitopes on the AA backbone of this glycoprotein, which thereby define tumor-specific antigens.
The expression of this protein in normal cells is low and restricted to the apical surface of normal epithelial cells, whereas in the cancerous epithelial cells, the level of expression is dramatically upregulated and found on all surfaces of the epithelial cell. 20, 21 Upregulation of expression of the mucin-1 protein in over 90% of carcinomas of the breast, lung colon, prostate and ovary is associated with a poor prognosis, decreased time to progression, metastases and chemotherapy resistance. 22, 23 We chose a 40-AA region that contained two tandem 20 AA repeats of the ecd of the mucin-1 protein and attached it through a 17-AA linker to the amino-terminal end of the ecd of the CD40L. We made both the Ad-sig-hMUC-1/ecdCD40L adenoviral vector and the hMUC-1/ecdCD40L proteins for boosting. Over 80% of the protein was in the homo-trimeric state. We compared various schedules of administration of the vector and protein boost. It was found that an initial administration of a single vector injection followed in 7 and 21 days with protein boosts was the best schedule in terms of the magnitude of increase of the hMUC-1-specific CD8 effector T cells and antibodies. 5 The antibodies induced in the mice bound to human breast and prostate cancer histopathological specimens. 5 Both the V V V and the VPP completely prevented the engraftment and growth of hMUC-1-positive tumor cells in hMUC1.Tg mice. 5 The VPP completely cleared established SC nodules, whereas the administration of the V V V vaccine only partially cleared the pre-existing SC nodules of hMUC-1-positive tumor nodules in hMUC1.Tg mice. 
PHASE I TRIAL OF THE AD-SIG-HMUC-1/ECDCD40L VECTOR PRIME-PROTEIN BOOST IN HUMAN SUBJECTS
A phase I trial of the toxicity and efficacy of the Ad-sig-hMCU-1/ ecdCD40L in patients with relapsed carcinomas of the breast, lung, colon, prostate and ovary will be conducted at the National Cancer Center of Singapore by Dr Han Chong Toh and his group. The endpoints of the trial will be toxicity, and tumor response as measured by CT scans and the serum levels of hMUC-1. Twelve patients who are ECOG performance status 0-2 will be eligible. There will be four dose cohorts of 1 billion, 10 billion, 50 billion and 100 billion Ad-sig-hMUC-1/ecdCD40L viral particles, administered as a single SC injection. This will be a standard 3 þ 3 phase I design.
Dr John Connelly of the Immunology Network in Singapore will collect peripheral blood mononuclear cells from the patients before and after vaccination. Then he will use multiplex ELISA to measure the levels of the following cytokines in these cells before and after vaccination: IL1, IL2, IL5, IL12, IL4, IL10, IL17, tumor necrosis factor-a. He will make these measurements in various subsets of the peripheral blood mononuclear cells. He will also test if there are dectectable levels of antibodies to the Ad-sig-hMUC-1/ ecdCD40L vector.
The Toh group will then conduct a study of a second cohort of 12 patients, each receiving the best dose of the Ad-sig-hMUC-1/ ecdCD40 from the first 12 patients, followed by two SC injections of the hMUC-1/ecdCD40L protein boost administered at 7 and 21 days. The dose of the Ad-sig-hMUC-1/ecdCD40L vector will be the same in all four cohorts of three patients each, whereas the dose of the hMUC-1/ecdCD40L protein boost will be increased in a standard 3 þ 3 phase I design. The eligibility and endpoints will be the same as in the first 12 patients.
APPLICATION OF THE TAA/ECDCD40L VACCINE TO INFECTIOUS DISEASES
This TAA/ecdCD40L vaccine is being developed for influenza, plague, MRSA, Rift Valley fever virus, Dengue virus and anthrax. The experience to date with the hemagglutinin (HA) and M2 influenza antigen TAA/ecdCD40L vaccines, which has been published, 8 will be presented. Three fragments from the cellular receptor contact region of HA and the ecd of M2 were attached to the ecdCD40L and both Adsig-TAA/ecdCD40L V Vs and TAA/ecdCC40LL protein boost vaccines were produced. Experiments in 18-month and 2-month-old test mice of the VPP schedule for both the HA/ecdCD40L and the M2/ecdCD40L vaccines showed substantial increments in both TAA-specific CD8 effector T cells and antibodies in both 2-month and 18-month-old mice. 8 Interestingly, the levels of increase in the TAA-specific T cells and antibodies with M2, usually a weak immunogen, were similar to that seen with the HAA/ecdCD40L vaccine. 8 This is notable as M2 is usually considered to be a much weaker immunogen than HA suggesting that the attachment of the M2 to the CD40L makes M2 a much more potent immunogen. 8 Neutralizing antibodies to the influenza virus were observed both with the M2 and HA vaccine, with titers above 1/ 4000 in the case of the HA/ecdCD40L vaccine. 8 
CONCLUSIONS
The TAA/ecdCD40L vaccine platform has been shown to: overcome anergy in TAA.Tg anergic transgenic mice, to induce a memory response of greater than 1 year, to be antigen specific, to induce an immune response, which is greater than that observed with Ad-sig-TAA alone, to induce resistance to engraftment of TAA-positive tumor cell lines, to induce regressions of existing tumor nodules, to make weak antigens much more potent antigens, and to induce high levels of neutralizing antibodies to foreign antigens on viral infectious agents. This vaccine platform, which is being tested at the phase I level in human subjects, appears to have potential both for cancer and infectious disease applications.
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